Short Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Expands By 725.9%

GlucoTrack, Inc. (NASDAQ:GCTK) was the target of a significant growth in short interest in May. As of May 29th, there was short interest totaling 363,693 shares, a growth of 725.9% from the May 14th total of 44,035 shares. Approximately 5.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 750,364 shares, the days-to-cover ratio is presently 0.5 days.

GlucoTrack Price Performance

Shares of GCTK stock traded down $0.08 during trading hours on Wednesday, reaching $0.42. The company’s stock had a trading volume of 433,980 shares, compared to its average volume of 2,888,848. The firm’s 50 day simple moving average is $0.70 and its 200-day simple moving average is $2.31. The company has a market capitalization of $2.62 million, a price-to-earnings ratio of -0.02 and a beta of 0.72. GlucoTrack has a fifty-two week low of $0.42 and a fifty-two week high of $15.90. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 0.08.

Wall Street Analyst Weigh In

GCTK has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a research report on Tuesday, April 21st. Wall Street Zen raised GlucoTrack to a “sell” rating in a research report on Saturday, May 30th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On GlucoTrack

Large investors have recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in shares of GlucoTrack by 102,125.0% in the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after purchasing an additional 4,085 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of GlucoTrack during the 4th quarter valued at $52,000. Finally, Ikarian Capital LLC acquired a new stake in shares of GlucoTrack during the 4th quarter valued at $177,000. Institutional investors and hedge funds own 10.92% of the company’s stock.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.